Text size :

Drugs, Pavesi (Aifa): “Innovation and sustainability are not alternatives”

ADNKRONOS

November 9, 2026

Rome, Nov 9. (Adnkronos Health) –  

“On one hand, there’s costly innovation, with the increasing number of high-cost drugs that must be brought to the patient’s bedside, and on the other, the need to make the healthcare system financially sustainable. The two things are not alternatives: we must ensure innovation that is true innovation and not just a simple novelty.” This was stated by Giovanni Pavesi, administrative director of the Italian Medicines Agency (Aifa), speaking at the meeting ‘The future of pharmaceutical legislation: a systemic vision’, organized by Nuove Reti in Rome.

“At the same time, we must ensure that the value of innovation is such as to allow therapeutic improvements, reduced hospitalization, greater therapeutic adherence, and faster and more patient-proximate access channels – explained Pavesi -. In this framework, we will have a renewed healthcare system that will no longer focus on the cost of the drug, but on a drug policy.” “We have a government proposal in the budget on the topic of ‘early access’, with an allocation of 70 million euros in this first phase, to allow truly innovative drugs to go directly to authorization without waiting for the traditionally necessary process to reach commercial authorization. This is already a strong signal.”

“The other front is to try to be faster in authorizations and ensure that both Aifa’s timelines and those of the Regions in including the drug in their therapeutic formularies are guaranteed with certainty,” he concluded.

Jiji Press

Related

Page TOP